282 related articles for article (PubMed ID: 28467293)
1. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.
Chatham W; Chadha A; Fettiplace J; Kleoudis C; Bass D; Roth D; Gordon D
Lupus; 2017 Dec; 26(14):1483-1490. PubMed ID: 28467293
[TBL] [Abstract][Full Text] [Related]
2. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.
Nagel J; Saxne T; Geborek P; Bengtsson AA; Jacobsen S; Svaerke Joergensen C; Nilsson JÅ; Skattum L; Jönsen A; Kapetanovic MC
Lupus; 2017 Sep; 26(10):1072-1081. PubMed ID: 28420056
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment.
Rezende RP; Ribeiro FM; Albuquerque EM; Gayer CR; Andrade LE; Klumb EM
Lupus; 2016 Oct; 25(11):1254-9. PubMed ID: 26923283
[TBL] [Abstract][Full Text] [Related]
4. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
[TBL] [Abstract][Full Text] [Related]
5. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.
Chatham WW; Wallace DJ; Stohl W; Latinis KM; Manzi S; McCune WJ; Tegzová D; McKay JD; Avila-Armengol HE; Utset TO; Zhong ZJ; Hough DR; Freimuth WW; Migone TS;
J Rheumatol; 2012 Aug; 39(8):1632-40. PubMed ID: 22707609
[TBL] [Abstract][Full Text] [Related]
6. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.
Sheikh SZ; Hammer AE; Fox NL; Groark J; Struemper H; Roth D; Gordon D
Int J Clin Pharmacol Ther; 2016 Nov; 54(11):914-922. PubMed ID: 27668697
[TBL] [Abstract][Full Text] [Related]
8. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.
Bruce IN; Urowitz M; van Vollenhoven R; Aranow C; Fettiplace J; Oldham M; Wilson B; Molta C; Roth D; Gordon D
Lupus; 2016 Jun; 25(7):699-709. PubMed ID: 26936891
[TBL] [Abstract][Full Text] [Related]
9. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
10. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.
Struemper H; Thapar M; Roth D
Clin Pharmacokinet; 2018 Jun; 57(6):717-728. PubMed ID: 28887801
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
[TBL] [Abstract][Full Text] [Related]
14. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
[TBL] [Abstract][Full Text] [Related]
15. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK
J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
[TBL] [Abstract][Full Text] [Related]
16. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
18. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
[TBL] [Abstract][Full Text] [Related]
19. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Struemper H; Roth D
Mod Rheumatol; 2019 May; 29(3):452-460. PubMed ID: 29792370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]